[Review of the evidence about drugs used as SYSADOA].
Sanfélix-Gimeno
Gabriel
G
Escuela Valenciana de Estudios de la Salud, Valencia, España. sanfelix_gab@gva.es
Reig-Mollá
Begoña
B
Sanfélix-Genovés
José
J
Giner-Ruiz
Vicente
V
D000284:Administration, Oral; D000880:Anthraquinones / Q000008:administration & dosage / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002809:Chondroitin Sulfates / Q000008:administration & dosage / Q000627:therapeutic use; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D003692:Delayed-Action Preparations; D004341:Drug Evaluation / Q000706:statistics & numerical data; D019317:Evidence-Based Medicine; D005944:Glucosamine / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D006820:Hyaluronic Acid / Q000008:administration & dosage / Q000627:therapeutic use; D007270:Injections, Intra-Articular; D015201:Meta-Analysis as Topic; D010003:Osteoarthritis / Q000188:drug therapy*
D000880:Anthraquinones; D000894:Anti-Inflammatory Agents, Non-Steroidal; D018501:Antirheumatic Agents; D003692:Delayed-Action Preparations; C025292:diacerein; D006820:Hyaluronic Acid; D002809:Chondroitin Sulfates; D005944:Glucosamine